%0 Journal Article
%A Baumgartner, Tobias
%A Freyberg, Moritz
%A Campetella, Lucia
%A Crijnen, Yvette
%A Dargvainiene, Justina
%A Behning, Charlotte
%A Bien, Christian G
%A Rada, Anna
%A Prüss, Harald
%A Rössling, Rosa
%A Kovac, Stjepana
%A Strippel, Christine
%A Thaler, Franziska S
%A Eisenhut, Katharina
%A Lewerenz, Jan
%A Becker, Felicitas
%A Reinecke, Raphael
%A Malter, Michael Peter
%A Sühs, Kurt-Wolfram
%A Tauber, Simone C
%A Von Podewils, Felix
%A Melzer, Nico
%A Wandinger, Klaus-Peter
%A Fernandez Ceballos, Romina-Anna-Maria
%A Kuhle, Jens
%A Berger, Klaus
%A Bauer, Tobias
%A Rüber, Theodor
%A Racz, Attila
%A Becker, Albert J
%A Pitsch, Julika
%A Kuhlenbäumer, Gregor
%A Muñiz-Castrillo, Sergio
%A Honnorat, Jerome
%A Titulaer, Maarten J
%A Leypoldt, Frank
%A Surges, Rainer
%T Risk of Epilepsy and Factors Associated With Time to Seizure Remission in Anti-LGI1 Encephalitis: Long-Term Outcome in 236 Patients.
%J Neurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology
%V 12
%N 6
%@ 2332-7812
%C Philadelphia, Pa.
%I Wolters Kluwer
%M DZNE-2026-00014
%P e200469
%D 2025
%X Autoimmune encephalitis (AIE) with anti-leucine-rich glioma-inactivated 1 (LGI1) antibodies typically manifests with subacute cognitive deficits, seizures, and psychiatric symptoms, mostly in older adults. Immunotherapy (IT) leads to the cessation of seizures in most patients, yet some develop AIE-associated epilepsy (AEAE) and persistent cognitive deficits. The aim of this large multicentric retrospective observational cohort study was to assess long-term outcomes of patients with anti-LGI1 encephalitis regarding seizures and AEAE and to identify associated factors.We included patients with anti-LGI1 encephalitis from 3 national referral centers/consortia meeting the following inclusion criteria: (I) definite LGI1 limbic encephalitis (Graus criteria); (II) occurrence of seizures; and (III) follow-up period ≥24 months. We aimed to (1) determine the risk of seizure recurrence (ROSR) on remission, (2) investigate clinical and paraclinical biomarkers for an effect on time to seizure remission using Cox proportional hazard modeling (n = 188), and (3) assess the risk of AEAE and determine associated factors (n = 236).AEAE was observed in 5.9
%K Humans
%K Female
%K Male
%K Middle Aged
%K Retrospective Studies
%K Adult
%K Aged
%K Epilepsy: etiology
%K Epilepsy: epidemiology
%K Autoantibodies: blood
%K Seizures: etiology
%K Encephalitis: complications
%K Encephalitis: immunology
%K Autoimmune Diseases of the Nervous System: complications
%K Autoimmune Diseases of the Nervous System: immunology
%K Autoimmune Diseases of the Nervous System: therapy
%K Limbic Encephalitis: complications
%K Limbic Encephalitis: immunology
%K Follow-Up Studies
%K Intracellular Signaling Peptides and Proteins: immunology
%K Young Adult
%K Autoantibodies (NLM Chemicals)
%K LGI1 protein, human (NLM Chemicals)
%K anti-leucine-rich glioma-inactivated 1 autoantibody (NLM Chemicals)
%K Intracellular Signaling Peptides and Proteins (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40953325
%2 pmc:PMC12440303
%R 10.1212/NXI.0000000000200469
%U https://pub.dzne.de/record/283118